A Phase 1/2 interventional study of intravenous treatment with EVs and intravenous treatment with placebo solution in Severe Acute Respiratory Syndrome (SARS), Acute Respiratory Distress Syndrome (ARDS) and Pneumonia, sponsored by D'Or Institute for Research and Education. Not yet recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-21.
Sponsored by D'Or Institute for Research and Education · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Severe Acute Respiratory Syndrome with a site in Brazil — 3 open to participants now, 4 under way, 2 of them phase 3. Severe Acute Respiratory Syndrome · Brazil.
Among the 29 studies in Severe Acute Respiratory Syndrome with a site in Brazil, this one is the 22nd largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2024, is one of 2 in phase 1/2, and was the 29th registered.
376 studies on the registry are indexed under Severe Acute Respiratory Syndrome; 14 are open to participants now.
Browse Severe Acute Respiratory Syndrome studies →3 of the 29 studies in Severe Acute Respiratory Syndrome with a site in Brazil are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Brazil, United States, Argentina and 36 more countries
Ages 18+
Cardresearch · Sites in Brazil
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 7 Severe Acute Respiratory Syndrome studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 13 · Phase 4 1
First in 2020; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 140 across 210 interventional studies indexed under Severe Acute Respiratory Syndrome.
Median enrollment 279 across the 26 interventional studies, 250 across the 3 observational. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 29 have an industry lead sponsor. The 10 most frequent:
D'Or Institute for Research and Education is the lead sponsor of 42 studies on the registry; 13 are open to participants now.
D'Or Institute for Research and Education has 1 study filed under Severe Acute Respiratory Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Severe Acute Respiratory Syndrome with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Severe Acute Respiratory Syndrome with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase I/II, randomized, double-blind, placebo-controlled clinical trial that will evaluate the safety and potential efficacy of therapy with extracellular vesicles (EVs) obtained from mesenchymal stromal cells (MSCs), patients with moderate to severe acute respiratory distress syndrome due to COVID-19 or other etiology. Participants will be allocated to receive EVs obtained from MSCs or placebo (equal volume of Plasma-Lyte A). Blinding will cover the participants, the multidisciplinary intensive care team and the investigators.
The studied population will consist of 15 patients diagnosed with acute respiratory failure syndrome admitted to the intensive care unit of Hospital São Rafael. This research aims to assess the safety and potential effectiveness of intravenous therapy using extracellular vesicles derived from mesenchymal cells in patients with moderate to severe acute respiratory distress syndrome. The treatment group will receive intravenous administration of extracellular vesicles obtained from mesenchymal cells, while the control group will receive a placebo.
EV group: will consist of 10 participants who will receive two infusions of 25 mL of the investigational product (Plasma-Lyte A solution containing EVs obtained from MSCs), intravenously, at intervals of 48 h.
Placebo group: will consist of 5 participants who will receive an equal volume of Plasma-Lyte A, intravenously, following the same schedule as the IV group: two infusions with an interval of 48 hours.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
will consist of 10 participants who will receive two infusions of 25 mL of the investigational product (Plasma-Lyte A solution containing EVs obtained from MSCs), intravenously, at intervals of 48 h.
Biological: intravenous treatment with EVs
will consist of 5 participants who will receive an equal volume of Plasma-Lyte A, intravenously, following the same schedule as the IV group: two infusions with an interval of 48 hours.
Biological: intravenous treatment with placebo solution
intravenous treatment with extracellular vesicles
intravenous treatment with placebo solution (without extracellular vesicles)
Measure administration of extracellular vesicles (EVs) up to 28 days
Measure as reported adverse events up to 28 days after treatment or placebo administration to evaluate safety of treatment
Time frame: 28 days
All-cause mortality
at days 14 and 28 after randomization;
Time frame: Day 14 and day 28
Variation in the Ratio PaO2/FiO2
PaO2 (arterial partial pressure of oxygen)/FiO2 (fraction of inspired oxygen) on the day of randomization and at 24 hours, 48 hours and 7 days after the first infusion;
Time frame: Baseline, day 01, day 02 and day 07
Variation in the SOFA index
Variation in the SOFA index (Assessment of Sequential Organ Failure) at the time of randomization and during follow-up until discharge from the intensive care unit;
Time frame: day 01, day 02, day 07, day 09, day 14 and day 29
Exploratory laboratory analysis
variation in total and differential laboratory analysis.
Time frame: 30 days
Duration of the period of hospitalization
from hospital time in the intensive care unit (ICU)
Time frame: 30 days
Duration of the period of ICU ventilation
If applicable,will be measured the time of mechanical ventilation.
Time frame: 30 days
Plan to share: No
Start is estimated for Feb 2024; primary completion for Jun 2025, 16 months later.
Of 11 phase 1/2 interventional studies under Severe Acute Respiratory Syndrome, half reached primary completion within 5 months of starting (the median); a quarter within 3 and three quarters within 13. This study's planned 16 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Severe Acute Respiratory Syndrome →
D'Or Institute for Research and Education